Summary

• Immunic, Inc. (IMUX) is rated Hold due to high cash burn, heavy dilution, and reliance on a single near-term catalyst.
• Vidofludimus calcium (IMU-838) Phase 3 MS trial results, expected late 2026, are pivotal for IMUX's future revenue and valuation.
• Recent $187M private placement and $200M in warrants extend IMUX's cash runway to Phase 3 readout, and hopefully to the drugs rollout to the market, reducing near-term dilution risk.
• If Vidofludimus calcium fails, IMUX faces severe downside as backup assets are 6–10 years from market, risking insolvency.

Immunic, Inc. (IMUX) is a pre-revenue company listed on the NASDAQ, in the stage of clinical drug development, which means that they are burning millions of dollars for R&D (research and development) of new therapeutic assets. Because the company

22 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.